• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    ALTIVIA Appoints Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager

    4/8/24 12:44:00 PM ET
    $DOW
    $PFE
    Major Chemicals
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DOW alert in real time by email

    HOUSTON, April 8, 2024 /PRNewswire/ -- ALTIVIA today announced that it has named Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager.

    Scott Barnum, Director of Manufacturing

    Mr. Barnum will oversee the process management, quality, and operations of ALTIVIA's Specialty and Oxide Chemicals' units. Mr. Hale will lead the development and management of ALTIVIA's Corporate Engineering Department.

    "We look forward to welcoming both Scott and Dean as ALTIVIA furthers its investment in growth, sustainability, and world-class operating performance," said Michael Jusbasche, ALTIVIA's Chief Executive Officer. "Their proven leadership and experience in the chemicals industry will fuel ALTIVIA's growth."

    Scott Barnum

    Mr. Barnum has 30 years of experience in the chemicals industry, including phosgenation, chlorination, sulfonation, and esterification processes. Prior to joining ALTIVIA, Mr. Barnum served as the Director of Manufacturing at Niacet Corporation, a division of Kerry Group, plc (OTC Markets KRYAY), an industry-leading manufacturer in food feed, and pharmaceutical additives. Mr. Barnum served as board member of the Buffalo Niagara Manufacturing Alliance, representing 194 member companies.

    During his career, Mr. Barnum has been recognized for his contributions to environmental, safety, and health management. Mr. Barnum holds a Bachelor of Science in Chemical Engineering from The State University of New York.

    Dean Hale

    Mr. Hale has spent the last 33 years in various engineering capacities in the chemicals industry, focused on process development, implementation, and optimization. He brings a breadth of industry experience in applications including petrochemicals, semiconductor chemicals, pharmaceuticals, and food additives. Prior to joining ALTIVIA, he most recently served as the Engineering Manager for Niacet Corporation, a division of Kerry Group, plc (OTC Markets: KRYAY), and has held various engineering and project management roles for DOW (NYSE:DOW) and Pfizer (NYSE:PFE).

    Mr. Hale has been a recipient of the Pfizer Innovation Award and the Teamwork Award, and Pharmacia's Outstanding Performance Recognition Award. Mr. Hale holds a Bachelor of Science in Chemical Engineering from Michigan State University and is certified as a Project Management Professional.

    Mr. Barnum's and Mr. Hale's leadership were instrumental in Niacet's winning the American Chemistry Council's (ACC) Company of the Year Award for outstanding environmental, safety, health, and security performance.

    About ALTIVIA

    Headquartered in Houston, Texas, privately held ALTIVIA was founded in 1986 and today operates four petrochemical and specialty chemical manufacturing facilities in Texas, Ohio, and West Virginia.

    • ALTIVIA Petrochemicals, with facilities in Haverhill, Ohio, is the third largest merchant producer of Phenol, Acetone, and alpha-methyl-styrene in the Americas.
    • ALTIVIA Specialty Chemicals, the largest producer of Phosgene derivative intermediates in the Americas, including chloroformates and acid chlorides, serving the pharmaceutical, organic peroxide, and agricultural markets from its operations in LaPorte, Texas.
    • ALTIVIA Ketones & Additives, a global leader and producer of ketones and carbinols at its facilities in Institute, West Virginia. This business was acquired from The Dow Chemical Company in 2019, and it serves the coatings, industrial and automotive lubricants, and adhesives industries.
    • ALTIVIA Oxide Chemicals specializes in custom production of various chemical intermediates serving surfactant, lubricant, and fuel additives markets. The production facility in Crosby, Texas, includes 31 reactors and distillation trains with ethoxylation, propoxylation and a range of organic reaction capabilities.

    For more information contact:

    Kelly Kimberly

    +1.713.822.7538

    [email protected] 

    Dean Hale, Corporate Engineering Manager

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/altivia-appoints-scott-barnum-as-director-of-manufacturing-and-dean-hale-as-corporate-engineering-manager-302110654.html

    SOURCE ALTIVIA

    Get the next $DOW alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DOW
    $PFE

    CompanyDatePrice TargetRatingAnalyst
    Dow Inc.
    $DOW
    8/14/2025$25.00Underperform → Neutral
    BofA Securities
    Dow Inc.
    $DOW
    8/5/2025$40.00Neutral → Buy
    Rothschild & Co Redburn
    Dow Inc.
    $DOW
    7/25/2025$32.00Outperform → In-line
    Evercore ISI
    Dow Inc.
    $DOW
    6/23/2025$22.00Market Perform → Underperform
    BMO Capital Markets
    Pfizer Inc.
    $PFE
    4/22/2025$24.00Neutral
    Cantor Fitzgerald
    Dow Inc.
    $DOW
    4/15/2025$28.00Buy → Underperform
    BofA Securities
    Dow Inc.
    $DOW
    4/4/2025$31.00Overweight → Neutral
    Analyst
    Dow Inc.
    $DOW
    1/7/2025$60.00 → $53.00Overweight → Neutral
    Piper Sandler
    More analyst ratings

    $DOW
    $PFE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chairman & CEO Bourla Albert

    4 - PFIZER INC (0000078003) (Issuer)

    8/4/25 10:23:16 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chairman & CEO Bourla Albert

    4 - PFIZER INC (0000078003) (Issuer)

    7/16/25 6:20:20 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Taraporevala Cyrus

    4 - PFIZER INC (0000078003) (Issuer)

    7/2/25 4:39:02 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOW
    $PFE
    SEC Filings

    View All

    SEC Form 13F-HR filed by Pfizer Inc.

    13F-HR - PFIZER INC (0000078003) (Filer)

    8/11/25 5:08:12 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Pfizer Inc.

    10-Q - PFIZER INC (0000078003) (Filer)

    8/5/25 7:16:27 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - PFIZER INC (0000078003) (Filer)

    8/5/25 7:08:22 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOW
    $PFE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Blaylock Ronald E bought $499,072 worth of shares (19,457 units at $25.65), increasing direct ownership by 236% to 27,707 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    2/14/25 5:16:36 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Dial Debra L. bought $26,197 worth of shares (675 units at $38.81) (SEC Form 4)

    4 - DOW INC. (0001751788) (Issuer)

    2/11/25 4:15:26 PM ET
    $DOW
    Major Chemicals
    Industrials

    Director Banister Gaurdie E. Jr. bought $299,932 worth of shares (7,339 units at $40.87) (SEC Form 4)

    4 - DOW INC. (0001751788) (Issuer)

    12/17/24 4:59:47 PM ET
    $DOW
    Major Chemicals
    Industrials

    $DOW
    $PFE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $DOW
    $PFE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $DOW
    $PFE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    10/25/24 2:48:21 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for HYMPAVZI issued to PFIZER INC

    Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

    10/15/24 2:57:27 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

    For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

    10/11/24 2:12:15 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery

    PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in cisplatin-ineligible patients with muscle-invasive bladder cancer Results will be discussed with global health authorities for potential regulatory filings Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive topline results from the Phase 3 EV-303 clinical trial (also known as KEYNOTE-905). The EV-303 study is evaluating PADCEV™ (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with KEYTRUDA™ (pembrolizumab), a PD-1 inhibitor, as neoadju

    8/12/25 5:30:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

    – Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant – – Vepdegestrant is the first PROteolysis TArgeting Chimera (PROTAC) to demonstrate clinical benefit in patients with breast cancer – NEW HAVEN, Conn., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), today with its partner Pfizer Inc. (NYSE:PFE), announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for vepdegestrant for the treatment of patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (H

    8/8/25 4:05:04 PM ET
    $ARVN
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance

    Strengthened Commercial Execution Driving Topline Growth Continued Progress Across R&D Pipeline Expanded Programs On Track to Deliver Net Cost Savings Targets Pfizer Inc. (NYSE:PFE) reported financial results for the second quarter of 2025 and reaffirmed its 2025 Revenue guidance while raising guidance(1) for Adjusted(2) diluted EPS. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: "Pfizer had another strong quarter of focused execution and we're pleased with our progress in advancing our R&D pipeline, driving our commercial performance and expanding our margins. We continue to strengthen our company for the future and we're confident in our ability to cre

    8/5/25 6:45:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dow upgraded by BofA Securities with a new price target

    BofA Securities upgraded Dow from Underperform to Neutral and set a new price target of $25.00

    8/14/25 8:05:45 AM ET
    $DOW
    Major Chemicals
    Industrials

    Dow upgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn upgraded Dow from Neutral to Buy and set a new price target of $40.00

    8/5/25 7:03:19 AM ET
    $DOW
    Major Chemicals
    Industrials

    Dow downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Dow from Outperform to In-line and set a new price target of $32.00

    7/25/25 8:58:32 AM ET
    $DOW
    Major Chemicals
    Industrials

    $DOW
    $PFE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Dow Inc.

    SC 13G/A - DOW INC. (0001751788) (Subject)

    11/12/24 2:25:16 PM ET
    $DOW
    Major Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by Dow Inc.

    SC 13G/A - DOW INC. (0001751788) (Subject)

    11/4/24 11:51:32 AM ET
    $DOW
    Major Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by Dow Inc.

    SC 13G/A - DOW INC. (0001751788) (Subject)

    10/17/24 12:57:12 PM ET
    $DOW
    Major Chemicals
    Industrials

    $DOW
    $PFE
    Financials

    Live finance-specific insights

    View All

    Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance

    Strengthened Commercial Execution Driving Topline Growth Continued Progress Across R&D Pipeline Expanded Programs On Track to Deliver Net Cost Savings Targets Pfizer Inc. (NYSE:PFE) reported financial results for the second quarter of 2025 and reaffirmed its 2025 Revenue guidance while raising guidance(1) for Adjusted(2) diluted EPS. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: "Pfizer had another strong quarter of focused execution and we're pleased with our progress in advancing our R&D pipeline, driving our commercial performance and expanding our margins. We continue to strengthen our company for the future and we're confident in our ability to cre

    8/5/25 6:45:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dow declares quarterly dividend of 35 cents per share

    Adjusting dividend by 50% in response to prolonged industry downturnAligning payout size to ensure capital allocation flexibility and a balanced framework that enables higher returns for shareholders The Company continues to target a competitive dividend across the economic cycle MIDLAND, Mich., July 24, 2025 /PRNewswire/ -- Dow (NYSE:DOW) today announced that its Board of Directors has declared a dividend of 35 cents per share. The adjustment in payout size reflects Dow's balanced capital allocation approach and enhances financial flexibility amidst a persistently challenging macroeconomic environment.

    7/24/25 6:01:00 AM ET
    $DOW
    Major Chemicals
    Industrials

    Dow reports second quarter 2025 results

    MIDLAND, Mich., July 24, 2025 /PRNewswire/ -- Dow (NYSE:DOW): 2Q25 FINANCIAL HIGHLIGHTS Net sales were $10.1 billion, down 7% year-over-year, reflecting declines in all operating segments. Sequentially, net sales were down 3%, as seasonally higher demand in Performance Materials & Coatings was more than offset by declines across the other operating segments.Volume decreased 1% year-over-year, as gains in the U.S. and Canada were more than offset by declines in Europe, the Middle East, Africa and India (EMEAI). Sequentially, volume decreased 2%, as seasonally driven gains in Pe

    7/24/25 6:00:00 AM ET
    $DOW
    Major Chemicals
    Industrials

    $DOW
    $PFE
    Leadership Updates

    Live Leadership Updates

    View All

    Dow announces results from 2025 Annual Stockholder Meeting

    Declares quarterly dividend of 70 cents per shareRichard K. Davis re-elected independent lead directorMIDLAND, Mich., April 10, 2025 /PRNewswire/ -- Dow (NYSE:DOW) is pleased to report the results of its 2025 Annual Meeting of Stockholders. Today stockholders elected Samuel R. Allen, Gaurdie E. Banister Jr., Wesley G. Bush, Richard K. Davis, Jerri DeVard, Debra L. Dial, Jeff M. Fettig, Jim Fitterling, Jacqueline C. Hinman, Rebecca B. Liebert, Luis Alberto Moreno, Jill S. Wyant, and Daniel W. Yohannes to the Company's Board of Directors for one-year terms. Stockholders approved

    4/10/25 4:15:00 PM ET
    $DOW
    Major Chemicals
    Industrials

    Dexcom Appoints Jon Coleman as Chief Commercial Officer

    DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom's global commercial organization, including global sales, marketing and customer experience. Mr. Coleman joins Dexcom with more than 30 years of global commercial leadership experience across multiple healthcare segments and channels. Mr. Coleman served as an executive officer of Masimo Corporation (NASDAQ:MASI), where he held roles of increasing responsibility across his fifteen-year tenure. This included serving as president of Masimo's commercial teams where he oversaw the consolid

    3/25/25 4:05:00 PM ET
    $DXCM
    $MASI
    $PFE
    Medical/Dental Instruments
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Biotechnology: Pharmaceutical Preparations

    DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P

    3/7/25 6:19:00 PM ET
    $ALK
    $AMBC
    $ATI
    Air Freight/Delivery Services
    Consumer Discretionary
    Property-Casualty Insurers
    Finance